Groesbeck Investment Management Corp NJ decreased its stake in shares of Shire PLC (NASDAQ:SHPG) by 12.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 2,283 shares of the biopharmaceutical company’s stock after selling 326 shares during the period. Groesbeck Investment Management Corp NJ’s holdings in Shire PLC were worth $377,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Whittier Trust Co. boosted its position in Shire PLC by 19.1% in the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 92 shares during the last quarter. iAB Financial Bank boosted its position in Shire PLC by 34.3% in the first quarter. iAB Financial Bank now owns 5,820 shares of the biopharmaceutical company’s stock valued at $1,014,000 after buying an additional 1,485 shares during the last quarter. Braun Stacey Associates Inc. boosted its position in Shire PLC by 15.7% in the first quarter. Braun Stacey Associates Inc. now owns 64,658 shares of the biopharmaceutical company’s stock valued at $11,265,000 after buying an additional 8,789 shares during the last quarter. First Mercantile Trust Co. purchased a new position in Shire PLC during the first quarter valued at $354,000. Finally, Mycio Wealth Partners LLC purchased a new position in Shire PLC during the first quarter valued at $245,000. 20.22% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Shire PLC (NASDAQ SHPG) opened at 145.55 on Monday. Shire PLC has a 52 week low of $144.18 and a 52 week high of $209.22.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.53 by $0.20. The business had revenue of $3.75 billion during the quarter. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The company’s revenue was up 54.2% on a year-over-year basis. During the same quarter last year, the company posted $3.38 EPS. Equities analysts predict that Shire PLC will post $14.91 EPS for the current fiscal year.
The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be given a $0.1527 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is currently 40.63%.
Several equities analysts have recently weighed in on the company. Royal Bank Of Canada set a $221.00 price target on Shire PLC and gave the company a “buy” rating in a report on Thursday, May 18th. HSBC Holdings plc cut Shire PLC from a “hold” rating to a “reduce” rating in a report on Friday, May 19th. Sanford C. Bernstein cut Shire PLC from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $209.22 to $161.09 in a report on Thursday, May 25th. BidaskClub raised Shire PLC from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, ValuEngine cut Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $220.08.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.
